HGS starts dosing in Ph III Albuferon trial
USA-based Human Genome Sciences has initiated dosing in ACHIEVE 2/3, a Phase III clinical trial of its drug candidate Albuferon (albinterferon alfa-2b) in combination with Roche's Copegus (ribavirin) in treatment-naive patients with chronic hepatitis C genotypes 2 and 3.
ACHIEVE 2/3 is the second of two pivotal Phase III trials of the agent that HGS is conducting, with the goal of filing global marketing applications in 2009. Albuferon is also being developed by Swiss drug major Novartis under an exclusive worldwide development and commercialization agreement signed in June 2006.
According to HGS chief executive Thomas Watkins, "Albuferon could become the interferon of choice in treatment regimens for chronic hepatitis C." It is estimated that the condition affects as many as 170 million people worldwide, which includes nearly four million people in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze